<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01361802</url>
  </required_header>
  <id_info>
    <org_study_id>18.504</org_study_id>
    <nct_id>NCT01361802</nct_id>
  </id_info>
  <brief_title>Ambroxol Spray Sore Throat Study</brief_title>
  <official_title>A Multi-centre, Randomised, Double-blind, Placebo Controlled Parallel Group, Dose Finding Study to Assess the Efficacy and Safety of Ambroxol Spray (2.5mg, 5mg or 10mg) Versus Placebo for the Temporary Relief of Sore Throat Pain in Patients With Acute Pharyngitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The development of a new Ambroxol spray formulation for the treatment of sore throat pain
      associated with acute pharyngitis requires an initial phase II study to be conducted in order
      to select the most appropriate dose for pain relief.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the time-weighted average of the pain intensity difference (PID) from pre-dose baseline over the first two hours after the first spray application expressed as a ratio of the pre-dose baseline (SPIDnorm0-2h).</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients will record their pain intensity on the 11-point ordinal numerical rating scale in the diary additionally at 3 hours after the first spray application and the corresponding SPIDnorm0-3h</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients will record their pain intensity on the 11-point ordinal numerical rating scale in the diary additionally at 4, 6, 12 and 24 hours after the first spray application and the corresponding SPIDnorm0-24h</measure>
    <time_frame>4, 6, 12 and 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of efficacy at 3 and 24 hours after the first spray application will be assessed on a 5-point verbal rating scale.</measure>
    <time_frame>3 and 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">494</enrollment>
  <condition>Pharyngitis</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ambroxol Spray 2.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambroxol Spray Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambroxol Spray 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambroxol Spray Medium Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ambroxol Spray 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ambroxol Spray High dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol Spray</intervention_name>
    <description>low dose Ambroxol Spray</description>
    <arm_group_label>Ambroxol Spray 2.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol Spray</intervention_name>
    <description>medium dose Ambroxol Spray</description>
    <arm_group_label>Ambroxol Spray 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ambroxol Spray</intervention_name>
    <description>high dose Ambroxol Spray</description>
    <arm_group_label>Ambroxol Spray 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Spray</intervention_name>
    <description>Placebo Spray</description>
    <arm_group_label>Placebo Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Sore throat due to acute pharyngitis (not more than 72 hours);

          2. Score of 6 or greater on an 11-point pain intensity numerical rating scale;

          3. Willingness to remain at the study centre for one hour following the first dose of
             study medication and return one to three days later.

          4. Willing to take nothing by mouth except study medication for three hours following the
             first intake of study medication. Patients must also not smoke during this time
             period.

        Exclusion criteria:

          1. Known allergy to and/or hypersensitivity to ambroxol, sorbitol, or Acetaminophen;

          2. Patients with drug dependence and/or alcohol abuse;

          3. Use of any throat lozenge, throat spray, cough drop, menthol-containing product, or
             any product with demulcent properties within last 2 hours;

          4. Use of any analgesic/anti-pyretic within last 4 hours;

          5. Use of any &quot;cold medication&quot; (e.g. decongestant, antihistamine, expectorant,
             anti-tussive) within last eight hours;

          6. Use of an antibiotic for an acute illness within last 24 hours;

          7. Use of inhaled steroids or beta-agonists on a continuous basis during the last week;

          8. Use of any investigational therapy (including a marketed drug taken for an
             investigational indication) within last 30 days

          9. Any sign of mouth-breathing due to nasal congestion;

         10. Cough that causes throat discomfort;

         11. Active pulmonary disease such as bronchopneumonia;

         12. Pregnant, lactating or breastfeeding women,

         13. Any medical or psychiatric condition which, in the opinion of the investigator, could
             increase the risks associated with participation in an investigational study or affect
             compliance with the protocol.

         14. Patients who have previously enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>18.504.27015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Klipspruit West</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Krugersdorp</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lenasia</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newtown</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paarl</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>18.504.27009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sydenham</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2011</study_first_posted>
  <disposition_first_submitted>April 30, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 16, 2014</disposition_first_posted>
  <last_update_submitted>April 30, 2014</last_update_submitted>
  <last_update_submitted_qc>April 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambroxol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

